{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+the+Skin+and+Subcutaneous+Tissue&page=2",
    "query": {
      "condition": "Diseases of the Skin and Subcutaneous Tissue",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+the+Skin+and+Subcutaneous+Tissue&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:24:05.454Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01636687",
      "title": "Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 150mg",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2012-10-17",
      "completion_date": "2016-10-27",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01636687"
    },
    {
      "nct_id": "NCT03195322",
      "title": "Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Postoperative Pain",
        "Postoperative Nausea and Vomiting",
        "Quality of Life",
        "Breast Cancer",
        "Breast Prosthesis; Pain"
      ],
      "interventions": [
        {
          "name": "Pre-pectoral Tissue Expander",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-10-01",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2021-12-16",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03195322"
    },
    {
      "nct_id": "NCT04803305",
      "title": "Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Pancreatic Cancer",
        "Colorectal Cancer",
        "Prostate Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Loss of Appetite",
        "Fatigue",
        "Cachexia",
        "Anorexia"
      ],
      "interventions": [
        {
          "name": "PF-06946860",
          "type": "DRUG"
        },
        {
          "name": "Placebo for PF-06946860",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-05-11",
      "completion_date": "2022-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Camarillo",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04803305"
    },
    {
      "nct_id": "NCT04656418",
      "title": "CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "CSL312",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2021-01-27",
      "completion_date": "2022-06-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04656418"
    },
    {
      "nct_id": "NCT04908475",
      "title": "Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 352,
      "start_date": "2021-06-09",
      "completion_date": "2023-04-20",
      "has_results": true,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04908475"
    },
    {
      "nct_id": "NCT07007637",
      "title": "A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Sonelokimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MoonLake Immunotherapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 835,
      "start_date": "2025-06-27",
      "completion_date": "2028-06-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07007637"
    },
    {
      "nct_id": "NCT01217814",
      "title": "Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Folic/folinic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 4,
      "location_summary": "Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more",
      "locations": [
        {
          "city": "Freehold",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217814"
    },
    {
      "nct_id": "NCT02748863",
      "title": "Study of Secukinumab With 2 mL Pre-filled Syringes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 2 mL form",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 1 mL form",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2016-12-12",
      "completion_date": "2018-06-08",
      "has_results": true,
      "last_update_posted_date": "2019-07-15",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Fremont, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748863"
    },
    {
      "nct_id": "NCT01196091",
      "title": "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Connective Tissue Disease",
        "Autoimmune Disease"
      ],
      "interventions": [
        {
          "name": "LY2127399",
          "type": "DRUG"
        },
        {
          "name": "Placebo every 2 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo every 4 weeks",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1164,
      "start_date": "2010-12",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-12",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 88,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 85 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01196091"
    },
    {
      "nct_id": "NCT01009242",
      "title": "To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Arthritis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CDP6038",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo IV",
          "type": "OTHER"
        },
        {
          "name": "Placebo SC",
          "type": "OTHER"
        },
        {
          "name": "CDP 6038 SC",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-10",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-05-21T23:24:05.454Z",
      "location_count": 3,
      "location_summary": "Duncansville, Pennsylvania • Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009242"
    }
  ]
}